User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Multicentre, prospective, open study to evaluate the safety and efficacy of hylan G-F 20 in knee osteoarthritis subjects presenting with pain following arthroscopic meniscectomy

Primary tabs

Huskin, J. P. Dubuc, Jean-Emile [UCL] Vandekerckhove, B. Delince, P. Verdonk, Robert [UCL] Handelberg, F.

The aim of the study was to evaluate the safety and efficacy of viscosupplementation with hylan G-F 20 in patients with mild to moderate osteoarthritis (OA) presenting with persistent knee pain 4-12 weeks after arthroscopic meniscectomy. A prospective, multi-centre, open study was carried out in patients with pain due to OA of the knee, not resolved by simple analgesics, 4-12 weeks after undergoing arthroscopic meniscectomy. To be eligible, patients had to score >= 50 mm and <= 90 mm on both walking pain and patient global assessment visual analogue scales (VAS; 0-100 mm) at baseline and be radiologically diagnosed pre-operatively with OA grade I or II on the Kellgren-Lawrence scale, with < 50% joint space narrowing. Patients received three intra-articular, 2 ml injections of hylan G-F 20 in the target knee with an interval of 1 week between injections, and were followed for 52 weeks. The primary efficacy endpoint was the change from baseline in the walking pain VAS score at 26 weeks. Secondary outcome measures were the walking pain VAS scores at all other time points, the WOMAC Index at all time points, and patient and physician global assessment at all time points. The safety of the treatment was assessed using adverse event (AE) reports. A total of 62 patients (mean age 55.4 years, 52% male) were enrolled. The mean walking pain VAS score decreased by 36.8 mm from baseline at 26 weeks (P < 0.0001), and also showed statistically significant decreases (P < 0.0001) at all other time points. The change in WOMAC total and subscale scores from baseline were statistically significant (P < 0.0001) at all time points, as were the decreases in the physician and patient global assessment VAS scores. There were 18 target knee AEs (mostly pain and/or swelling and/or effusion) in 12 patients (19%) considered to be at least possibly related to treatment. The majority of these (78%) were mild or moderate in intensity. One patient (1.6%) experienced a serious adverse event (synovitis) in the target knee that was considered possibly related to study treatment. Hylan G-F 20 provides effective pain relief and improves stiffness and physical function in patients with mild to moderate OA presenting with persistent osteoarthritic pain 4-12 weeks after arthroscopic meniscectomy. Symptomatic efficacy was maximised at 12 weeks and maintained at 26 and 52 weeks. The type (pain and/or swelling and/or effusion) and the intensity (mostly mild/moderate) of AEs reported in this study are similar to those reported in other trials in different patient populations, but the incidence was higher (19%). The risk/benefit of hylan G-F 20 in this particular population of patients is favourable.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2008
Language Anglais
Journal information "Knee Surgery, Sports Traumatology, Arthroscopy" - Vol. 16, no. 8, p. 747-752 (2008)
Peer reviewed yes
Publisher Springer (New York)
issn 0942-2056
e-issn 1433-7347
Publication status Publié
Affiliations UCL - Cliniques universitaires Saint-Luc
UCL
Keywords osteoarthritis ; arthroscopy ; hylan ; hyaluronan
Links
  1. Adams ME, Atkinson MH, Lussier AJ et al (1995) The role of viscosupplementation with hylan G-F 20 (Synvisc®) in the treatment of osteoarthritis of the knee: a Canadian multicentre trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthr Cartil 3:213–225
  2. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines (2000) Recommendations for the medical management of osteoarthritis of the hip and the knee: 2000 update. Arthritis Rheum 43:1905–1915
  3. Arrich J., Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis, 10.1503/cmaj.1041203
  4. Bagga H, Burkhardt D, Sambrook P et al (2006) Long- term effects of intraarticular hyaluronan on synovial fluid in osteoarthritis of the knee. J Rheumatol 33:946–950
  5. Bellamy N, Campbell J, Robinson V et al (2006) Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database of Systematic Reviews Issue 2. Art. No.: CD005321
  6. Bhattacharyya T, Gale D, Dewire P et al (2003) The clinical importance of meniscal tears demonstrated by magnetic resonance imaging in osteoarthritis of the knee. J Bone Joint Surg Am 85-A(1):4–9
  7. Kemper F, Gebhardt U, Meng T et al (2005) Tolerability and short-term effectiveness of hylan G-F 20 in 4253 patients with osteoarthritis of the knee in clinical practice. Curr Med Res Opin 21:1261–1269
  8. Lussier A, Cividino AA, McFarlane CA et al (1996) Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J Rheumatol 23:1579–1585
  9. Marshall KW (1999) Hylan G-F 20 (Synvisc®) salvage of patients failing a standardised arthroscopic debridement treatment algorithm. Poster presented at the 9th conference of the Orthopaedic Research Society International, 3-4 June 1999, Brussels, Belgium
  10. Matsusue Y, Thomson NL (1996) Arthroscopic partial medial meniscectomy in patients over 40 years old: a 5- to 11-year follow-up study. Arthroscopy 12(1):39–44
  11. Moseley JB, O’Malley K, Petersen NJ et al (2002) A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med 347:81–88
  12. Pendleton A, Arden N, Dougados M et al (2000) EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 59:936–944
  13. Raynauld JP, Torrance GW, Band PA et al (2002) A prospective, randomised, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthr Cartil 10:506–517
  14. Scale D, Wobig M, Wolpert W (1994) Viscosupplementation of osteoarthritic knees with hylan: a treatment schedule study. Curr Ther Res 55:220–232
  15. Waddell DD, Bricker DC (2006) Clinical experience with the effectiveness and tolerability of hylan G-F 20 in 1047 patients with osteoarthritis of the knee. J Knee Surg 19:19–27
  16. Wang CT, Lin J, Chang CJ et al (2004) Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. A meta-analysis of randomized controlled trials. J Bone Joint Surg Am 86-A:538–545
  17. Wobig M, Dickhut A, Maier R et al (1998) Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther 20:410–423
Bibliographic reference Huskin, J. P. ; Dubuc, Jean-Emile ; Vandekerckhove, B. ; Delince, P. ; Verdonk, Robert ; et. al. Multicentre, prospective, open study to evaluate the safety and efficacy of hylan G-F 20 in knee osteoarthritis subjects presenting with pain following arthroscopic meniscectomy. In: Knee Surgery, Sports Traumatology, Arthroscopy, Vol. 16, no. 8, p. 747-752 (2008)
Permanent URL http://hdl.handle.net/2078.1/36442